Alex Blyth, a serial biotech entrepreneur and inventor working across oncology and longevity science, has come to view immune competence as a key influence on healthspan, disease susceptibility, and the broader trajectory of aging. He says, "The body's capacity to distinguish accurately between healthy tissue and potential threats plays an important role in how well people age." Biological age, in this framing, may reflect a downstream expression of a more fundamental variable: the quality of immune judgment.
This perspective has emerged from more than two decades immersed in life sciences innovation. Blyth is the founder and former CEO of LIfT BioSciences, a company developing neutrophil-based immunotherapies designed to address solid tumors by rejuvenating innate immune responses. Over the course of his career, he has contributed to the development and commercialization of healthcare assets and has held strategic roles in healthcare consulting and biotech venture building.
Trained in both biological sciences and economics, he brings a systems-level lens to medicine, linking cellular biology with thinking about public health at a systems level. The loss of his mother to pancreatic cancer further sharpened his focus on immune resilience and early intervention. Today, through his new venture Viternity, he is expanding that work into preventive longevity, with an emphasis on measuring and strengthening immune competence before overt disease manifests.
The urgency of this exploration reflects broader demographic and economic trends. According to the World Health Organization, the proportion of the global population aged 60 and over is expected to nearly double from 12% in 2015 to 22% by 2050. At the same time, chronic conditions have become major determinants of quality of life and workforce participation. A World Economic Forum report notes that chronic diseases now rank among the leading causes of disability and absenteeism, placing increasing strain on health systems and economic productivity.
Meanwhile, the so-called longevity economy continues to expand. The sector is projected to reach $27 trillion by 2030. These trends point to a rising interest in approaches that extend not just lifespan but the number of years lived in good health.
Amid this landscape, Blyth proposes a reframing of aging itself. He argues that many structural changes associated with aging stem from a gradual decline in immune competence. "The immune system functions as a self-maintenance engine," he explains. "Its intelligence lies in recognizing what belongs, what poses risk, and how strongly to respond. When that innate judgement starts to dysfunction, essential body maintenance and biological systems start to break down."
Innate immune cells, in Blyth's framing, operate as continuous pattern-recognition sentinels: clearing senescent cells, coordinating tissue repair, and detecting early malignant changes. He suggests that biological aging is a reflection of a gradual erosion in the accuracy and proportionality of these friend versus foe judgments. Moreover, he points to a constellation of shifts that tend to emerge together, including the accumulation of senescent cells, heightened inflammatory signaling, slower repair, and reduced vigilance toward abnormal growth.
Blyth sees these changes not as isolated defects but as the cumulative imprint of long-term pressures on the immune system, including persistent viral exposure, metabolic strain, environmental stressors, and psychological stress. He argues that these repeated demands and our genetic propensities shape how effectively immune cells make decisions over time. "Immune aging reflects pressure over time," he says. "These declines in immune function can be measured, and what can be measured can be managed."
Throughout his work, Blyth emphasizes modulation and restoration rather than rigid categories of "strong" or "weak" immunity. "It is now widely acknowledged that people who have autoimmune diseases are far more likely to get cancer, which explodes this strong versus weak myth," Blyth notes. He views immune competence as a dynamic capacity, something that can fluctuate depending on context, environment, and support, rather than a permanent state. "In the cancer work I've done testing people, what we have often seen is that those with the best ability to fight cancer tend to be the same ones who are best at self-sparing," he says. "Suggesting that the ability to correctly identify friend from foe, and respond accordingly, is what is key."
Viternity's Immune-IQ™ AI platform represents his attempt to translate that insight into a practical tool. Immune-IQ™ evaluates immune competence across multiple functional dimensions, including pathogen defense, cancer recognition, senescent cell clearance, and self-tolerance. These data are integrated into a composite score intended to reflect the quality of immune decision-making. "Immune-IQ™ aims to capture the functional intelligence of the system," Blyth explains. "It asks how well immune cells, individually and collectively, distinguish friend from foe and respond accordingly and proportionately." By focusing on functional dynamics rather than static biomarkers, the platform seeks to track immune age as a variable distinct from chronological age and existing biological age clocks.
A complementary metric to this is Rejuvenation-IQ™, which examines regenerative capacity and tissue repair responsiveness. These measures aim to broaden the longevity conversation toward the systems that sustain biological equilibrium. Blyth envisions a framework that eventually incorporates additional dimensions such as skin age and fertility age, acknowledging that vitality encompasses appearance and reproductive health alongside internal physiology. He notes that discussions about longevity often emphasize molecular and metabolic clocks using combinations of known metrics rather than understanding at a cellular function level what is really happening. Integrating these dimensions, in his view, fosters a more comprehensive understanding of aging, healthspan,, and how to best manage it.
Blyth notes that Viternity is currently conducting a clinical study to examine how various supplements and pharmacological agents, which have received a lot of attention recently, really influence immune function as captured by Immune-IQ™ metrics. The goal is to generate empirical data on how interventions affect immune cell pathways, protein synthesis, and differentiation patterns. "As data accumulates, and we validate and refine our measurement systems, we plan to identify which biological circuits we can target with new medical interventions and existing drug libraries," he notes. Blyth sees this as the foundation for a new category of immuno-longevity therapeutics designed to support immune competence, and thus healthspan, over time.
In this emerging paradigm, years added to life (longevity) and life added to years (healthspan) converge around a single principle: the refinement of immune judgment. By elevating immune competence as a measurable and modifiable dimension of health, Blyth invites a fundamental shift in how aging is understood and navigated in the future.
